Material and Methods: In our clinic between 2014 and 2018, patients who underwent PPV with the diagnosis of diabetic vitreous hemorrhage (VH) and regularly followed for at least six months postoperatively were included in the study. Preoperative bevacizumab administered eyes were classified as group 1 and those not administered as group 2. The patients? demographic characteristics, preoperative bevacizumab administration time (1.25mg 0.05ml), patients? preoperative and postoperative follow-up periods, complications during and after surgery, and surgeries and treatment approaches due to complications were recorded.

Results: 68 eyes of 60 patients were included in the study. Preoperative mean BCVA logMAR was 2+0,9 in group 1 vs. 2,1+0,9 in group 2, with no showing a statistically significant difference (p=0,398). In the postoperative follow-up, the mean BCVA logMAR increased significantly in both groups (p <0.005 in each group), and the mean BCVA did not differ significantly between the groups (p>0.05). Intravitreal bevacizumab (1.25 mg/0.05ml) was administered to 29 of 68 eyes with diabetic VH (group1) (%42,64), a mean of 7.9 ± 9 days before the operation. It was also found that the incidence of postoperative early (?4 weeks) (p = 0.736) and late (> 4 weeks) (p = 0.556) vitreous hemorrhages did not make a significant difference between groups.

Conclusion: In diabetic vitreous hemorrhage, the effect of preoperatively applied bevacizumab on final visual acuity and developing rehemorrhage is limited. Keywords : Vitreous Hemorrhage, Diabetic Vitreous Hemorrhage, Bevacizumab, Vitrectomy